Arrowhead Pharmaceuticals publishes presentation on plozasiran's reduction of acute pancreatitis risk
ARWR•Arrowhead Pharmaceuticals published pooled phase 3 trial results showing acute pancreatitis events in 1% of plozasiran patients versus 5.1% with placebo over 12 months. Quarterly dosing reduced triglycerides by about 80%, while worsening glycemic control occurred in 14% versus 9%.
1. Trial results
Pooled results from the phase 3 SHASTA-3 and SHASTA-4 trials showed acute pancreatitis event rates of 1% with plozasiran and 5.1% with placebo over 12 months; the relative risk was 0.22 (P=0.008). Among patients with prior pancreatitis, rates were 3.3% and 37.1%, respectively. Quarterly dosing produced sustained triglyceride reductions of about 80%, and more than 90% of patients reached levels below 500 mg/dL. Worsening glycemic control occurred in 14% of plozasiran patients versus 9% with placebo, while overall adverse event rates were generally similar.
